Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Baxter completes enrolment for haemophilia drug trial

Baxter completes enrolment for haemophilia drug trial

14th November 2013

Baxter has announced the completion of enrolment for a phase III clinical trial of BAX 855, a promising investigational therapy for haemophilia A.

The extended half-life, recombinant factor VIII treatment is being trialled to assess its efficacy in reducing annualised bleed rates in both prophylaxis and on-demand treatment schedules, as well as its safety and pharmacokinetic profile.

It is based on the full-length Advate molecule, a product with ten years of real-world experience, and has been modified with PEGylation technology designed to extend its duration of activity in the body.

Over the course of the phase II/III PROLONG-ATE study, BAX 855 is being evaluated among 146 adult patients with previously-treated severe haemophilia A. Results from the trial will support planned regulatory filings in 2014.

Dr Anders Ullman, vice-president of global research and development in Baxter's bioscience business, said: "The BAX 855 development programme is a priority for Baxter as we evaluate the potential to provide an efficacious and safe treatment with an extended half-life for patients with haemophilia."

This comes after the firm submitted a marketing authorisation application to the European Medicines Agency for the haemophilia B therapy Rixubis last month.ADNFCR-8000103-ID-801660560-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.